Posted by Michael Wonder on 22 Feb 2019
ICER to publish upcoming assessment on additive cardiovascular disease therapies
22 February 2019 - Report will be subject of Midwest CEPAC meeting in September; open input now being accepted until 12 March 2019.
The Institute for Clinical and Economic Review announced today that it plans to assess the comparative clinical effectiveness and value of icosapent ethyl (Vascepa, Amarin Pharma) and rivaroxaban (Xarelto, Janssen Pharmaceuticals), additive cardiovascular disease therapies.
The report will be reviewed during a public meeting of the Midwest Comparative Effectiveness Public Advisory Council in September of 2019.
